FCSC Fibrocell Science Inc.

2
+0.01  (+1%)
Previous Close 1.99
Open 1.95
Price To Book 1.92
Market Cap 19516664
Shares 9,758,332
Volume 33,717
Short Ratio
Av. Daily Volume 131,786

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227825
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183412
  3. 8-K - Current report 181175250
  4. 8-K - Current report 181137677
  5. 8-K - Current report 181106367

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Laviv
Wrinkles
Phase 2 endpoints not met - June 2016
azficel-T
Chronic Dysphonia
Phase 2 interim data due 1Q 2019 with Phase 3 trial to commence 1H 2019.
FCX-007
Recessive dystrophic epidermolysis bullosa
Phase 1/2 enrollment to commence 3Q 2018.
FCX-013
Scleroderma

SEC Filings

  1. 8-K - Current report 181227825
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183412
  3. 8-K - Current report 181175250
  4. 8-K - Current report 181137677
  5. 8-K - Current report 181106367
  6. 8-K - Current report 181084710
  7. 8-K - Current report 181053942
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181004904
  9. 8-K - Current report 181003503
  10. EFFECT - Notice of Effectiveness 181003026